Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Cyclin Dependent Kinase 2 inhibitors in cancer therapy: an update


Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associated with tumor growth in multiple cancer types. Although the role of CDK2 in tumorigenesis has been controversial, emerging evidence proposes that selective CDK2 inhibition may provide a therapeutic benefit against certain tumors, and it continues to appeal as a strategy to exploit in anticancer drug development. Several small-molecule CDK2 inhibitors have progressed to the clinical trials. However, a CDK2-selective inhibitor is yet to be discovered. Here, we discuss the latest understandings of the role of CDK2 in normal and cancer cells, review the core pharmacophores used to target CDK2, and outline strategies for the rational design of CDK2 inhibitors. We attempt to provide an outlook on how CDK2-selective inhibitors may open new avenues for cancer therapy.

Type Journal
ISBN 0022-2623
Authors Tadesse, S.; Caldon, E. C.; Tilley, W.; Wang, S.
Responsible Garvan Author A/Prof Liz Caldon
Published Date 2019-05-01
Published Volume 62
Published Issue 9
Published Pages 4233-4251
Status Published in-print
DOI 10.1021/acs.jmedchem.8b01469
URL link to publisher's version